Akero(AKRO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Ganglof as Chief Technical Of icer -- SOUTH SAN FRANCISCO, Calif. August 9, 2024 /GLOBE NEWSWIRE/ – Akero Therapeutics, Inc ...